Alaunos Therapeutics (TCRT) Cash & Equivalents (2009 - 2026)

Alaunos Therapeutics has reported Cash & Equivalents for 18 years, with the latest figure at $354000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 10.97% year-over-year to $354000.0; the trailing twelve-month figure through Mar 2026 stood at $354000.0 (up 10.97% YoY), and the FY2025 full-year result was $1.4 million, up 26.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $354000.0, down from $1.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $68.3 million in Q1 2022, with the low at $319000.0 in Q1 2025.
• Historically, Cash & Equivalents has averaged $16.5 million across 5 years, with a median of $4.1 million in 2024.
• The largest YoY upside for Cash & Equivalents was 26.95% in 2025 against a maximum downside of 92.3% in 2025.
• Alaunos Therapeutics' Cash & Equivalents stood at $39.1 million in 2022, then plunged by 84.48% to $6.1 million in 2023, then tumbled by 82.0% to $1.1 million in 2024, then climbed by 26.95% to $1.4 million in 2025, then sank by 74.44% to $354000.0 in 2026.
• The last three Cash & Equivalents figures came in at $354000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.